Lupus & antiphospholipid syndrome
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol
Study context
- Population
- Patients persistently positive for aPL with refractory and/or non-criteria manifestations of antiphospholipid syndrome (APS), San Giovanni Bosco Hospital (Turin)planned
- Participants
- 15 participants
- Primary endpoint
- Safety and adverse events (safety and tolerability of belimumab given for 24 months)
- Follow-up
- 4, 16, 24, 36, 52 and 104 weeks
Methodological detailsinvestigator-initiated, single-centre, open-label, prospective
- Investigator-initiated
- Single-centre
- Open-label
- Prospective
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol. Clin Exp Rheumatol. Published 10 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →